Trusted Resources: News & Meetings
Latest announcements and gatherings
Horizon Therapeutics plc Reports Strong Third-Quarter 2019 Results
Horizon Therapeutics plc today announced its third-quarter 2019 financial results and raised the midpoint of its full-year 2019 adjusted EBITDA guidance.
“Our third-quarter performance underscores the strength of our commercial and R&D organizations,” said Timothy Walbert, chairman, president and chief executive officer, Horizon. “We generated record quarterly net sales in our orphan and rheumatology segment – including a record quarter for net sales of KRYSTEXXA, our medicine for uncontrolled gout – and the U.S. FDA also granted Priority Review of our BLA for teprotumumab, our biologic candidate for the treatment of active thyroid eye disease. We made great progress on all fronts during the quarter, including our market education activities related to teprotumumab, and remain excited about the prospect of being able to address the significant unmet need for patients living with active thyroid eye disease.”
myBinderRelated Content
-
Consensus Statement of the European Group on Graves’ Orbitopathy (EUGOGO) on Management of Graves’ Orbit...Graves’ orbitopathy (GO) constitutes a...
-
Gut Microbes May Play Role in Graves ’ Disease Diagnosis, Thyroid AutoimmunityThe abundance and diversity of intestina...
-
Clinical Characteristics of Patients Requiring a Second Dose of Radioactive Iodine for the Treatment of Graves’ Di...Graves’ disease is an autoimmune condi...
-
Eric Hink, MDEric Hink is Associate Professor of opht...
-
Horizon Therapeutics Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application...Horizon Therapeutics plc today announced...
-
Raymond Douglas, MD, PhDDr. Raymond Douglas is the Director of t...
-
Laura Periman, MDLaura Periman, MD is a board-certified o...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google